GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data ...
Medscape20h
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...